The 2009 Tobacco Control Act Tobacco gave the Food and Drug Administration (FDA) regulatory authority over tobacco products. One of the first actions of the FDA, under this law, was to develop graphic warnings to appear on cigarette packaging. Tobacco companies challenged the new warnings as a violation of their first amendment rights, and the court ruled for tobacco in R.J. Reynolds v. FDA. The ruling found that available research did not show that graphic warnings placed on cigarette packs were associated with changes in tobacco use behavior. This is because, in part, experimental research to date has relied on onetime exposure to graphic labels, and these paradigms are too brief to measure change in tobacco use behavior. This application develops and tests an experimental approach that simulates real-world and prolonged exposure to FDA graphic warnings. In collaboration with a large community-based behavioral health provider, smokers are recruited from three residential addiction treatment programs. Key features of residential treatment are: a concentration of smokers, daily patient contact in which experimental labels can be affixed to the patient's own cigarette packs, ability to observe changes in smoking behavior. The project creates the 9 approved FDA warnings using adherence paper and measures behavioral and communication impacts associated with prolonged exposure to the warnings. The design is a sequence of off-on-off-on recruitment periods, each lasting 4 months, during which participants are either exposed to transparent labels (attention control condition) or to graphic warnings (experimental condition) on their own cigarette packs. 450 smokers will be enrolled, evenly distributed across conditions. For each participant there is a baseline interview, a 30 day exposure period (to transparent or graphic labels) and a follow up interview. Behavioral measures include intent to quit, quit attempts, cigarettes per day, and initiation of cessation services. Communication measures include tobacco risk perception, impacts of cigarette pack warnings, and thoughts about abstinence. The general hypothesis is that persons exposed to graphic labels, compared to those in an attention control condition, are more likely to change smoking behavior. The short term goal is to test an original experimental approach that will improve understanding of how graphic labels affect smoking-related behavior. The long term goal is to provide scientific information in support of the FDA regulatory mission.

Public Health Relevance

This study tests a new approach to testing the FDA approved graphic cigarette package warning labels. After placing graphic warnings on cigarette packs of 450 smokers, over a 30 day period, it will measure changes in smoking behavior. If smoking behavior change is observed, this will address the limitation observed by the court {R.J. Reynolds v. FDA) and pave the way for implementation of the FDA graphic warnings.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA082103-15S2
Application #
8642427
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Marino, Michael A
Project Start
1999-08-05
Project End
2015-11-30
Budget Start
2013-12-01
Budget End
2014-05-31
Support Year
15
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Brunner, Katja; John, Constance M; Phillips, Nancy J et al. (2018) Novel Campylobacter concisus lipooligosaccharide is a determinant of inflammatory potential and virulence. J Lipid Res 59:1893-1905
Felix, Janine F; Joubert, Bonnie R; Baccarelli, Andrea A et al. (2018) Cohort Profile: Pregnancy And Childhood Epigenetics (PACE) Consortium. Int J Epidemiol 47:22-23u
Cobler, Lara; Zhang, Hui; Suri, Poojan et al. (2018) xCT inhibition sensitizes tumors to ?-radiation via glutathione reduction. Oncotarget 9:32280-32297
Li, Megan; Mulkey, Flora; Jiang, Chen et al. (2018) Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). Clin Cancer Res 24:4734-4744
Ryu, Jae Kyu; Rafalski, Victoria A; Meyer-Franke, Anke et al. (2018) Fibrin-targeting immunotherapy protects against neuroinflammation and neurodegeneration. Nat Immunol 19:1212-1223
Zhou, Yu; Zou, Hao; Yau, Christina et al. (2018) Discovery of internalizing antibodies to basal breast cancer cells. Protein Eng Des Sel 31:17-28
Tat, David; Kenfield, Stacey A; Cowan, Janet E et al. (2018) Milk and other dairy foods in relation to prostate cancer recurrence: Data from the cancer of the prostate strategic urologic research endeavor (CaPSUREā„¢). Prostate 78:32-39
Guydish, Joseph; Tajima, Barbara; Le, Thao et al. (2018) Do cigarette graphic warnings encourage smokers to attend a smoking cessation programme: a quasi-experimental study. Tob Control 27:43-49
Dvorak, Christopher C; Satwani, Prakash; Stieglitz, Elliot et al. (2018) Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study. Pediatr Blood Cancer 65:e27034
Fan, Qi Wen; Nicolaides, Theodore P; Weiss, William A (2018) Inhibiting 4EBP1 in Glioblastoma. Clin Cancer Res 24:14-21

Showing the most recent 10 out of 192 publications